BioSpace News Archive

Stoke Therapeutics reported results for Dravet syndrome studies showing clinically meaningful effects, including reductions in convulsive seizure frequency, supporting the potential for disease modification.

Merck’s Winrevair is the second PAH drug to get the FDA’s green light in the past week, following Johnson & Johnson’s Opsynvi, which won approval on Friday.

Mural Oncology plc announced its financial results for the fourth quarter and year ended December 31, 2023, and provided a business update.

Viking Therapeutics, Inc. announced positive results from the company’s Phase 1 multiple ascending dose clinical trial of an oral tablet formulation of VK2735, a dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors, in development for the potential treatment of metabolic disorders such as obesity.

BioLineRx Ltd., a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, reported its financial results for the year ended December 31, 2023, and provided recent corporate and portfolio updates.

Function Oncology, a company transforming the operating system of precision medicine with CRISPR-powered platform technology, announced an innovative research and development partnership with Volastra Therapeutics, a company pioneering novel approaches to treating cancer by targeting a tumor vulnerability known as chromosomal instability.

Cellares, a leader in the automation of cell therapy manufacturing and the world’s first Integrated Development and Manufacturing Organization, announced the addition of Christi Shaw to its Advisory Board.

Protagonist Therapeutics, Inc. announced it has randomized 241 patients in the ongoing Phase 3 VERIFY clinical trial evaluating rusfertide in polycythemia vera as of and expects to meet the trial’s 250 patient enrollment target by the end of March 2024.

Theralase® Technologies Inc. announced that it is hosting Advisory Board meetings to present the latest Study II interim clinical data to its Principal Investigators at the Canadian Urological Association Bladder Cancer Forum and the American Urology Association, respectively.

A blood test that analyzes levels of amyloid proteins by highly sensitive mass spectrometry could help physicians establish that Alzheimer’s disease is likely not the cause of patients’ mild cognitive impairment, finds a new study published in Frontiers in Neurology by researchers from Quest Diagnostics, the University of Florida and Mount Sinai Medical Center in Miami Beach.